Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
WOBURN, MA / ACCESSWIRE / April 26, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that...
Biofrontera Inc. Makes Transformative Investment in Its’ Dermatology Salesforce
WOBURN, MA / ACCESSWIRE / March 27, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that...
Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
WOBURN, MA / ACCESSWIRE / March 8, 2023 / Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial...
Biofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2022
WOBURN, MA / ACCESSWIRE / January 9, 2023 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary,...